Analysis of the virus dynamics model reveals that early treatment of HCV infection may lead to the sustained virological response

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Gupta, Saurabh ^a   Singh, Raghvendra ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY KANPUR   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CONTROLLED STUDY; DISEASE COURSE; EARLY DIAGNOSIS; EARLY INTERVENTION; HEPATITIS C; INFECTION CONTROL; MATHEMATICAL MODEL; SCREENING TEST; SENSITIVITY ANALYSIS; SIMULATION; STEADY STATE; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT RESPONSE; VIRAL PHENOMENA AND FUNCTIONS; VIROGENESIS; VIRUS DYNAMICS; VIRUS INHIBITION; VIRUS LOAD;

ALGORITHMS; ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MODELS, BIOLOGICAL; TREATMENT OUTCOME; VIRAL LOAD;

HEPATITIS C VIRUS;

EID: 84864214889     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041209     Document Type: Article

References (48)

1. Lauer GM, Walker BD, (2001) Hepatitis C virus infection. N Engl J Med 345: 41-52.
2. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, et al. (2006) The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 144: 705-714.
3. Di Bisceglie AM, (1998) Hepatitis C. Lancet 351: 351-355.
4. Saito I, Miyamura T, Ohbayashi A, Harada H, Katayama T, et al. (1990) Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci U S A 87: 6547-6549.
5. Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, et al. (1998) The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 4: 1065-1067.
6. Feld JJ, Hoofnagle JH, (2005) Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436: 967-972.
7. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, et al. (1998) Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 339: 1485-1492.
8. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, et al. (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958-965.
9. Hezode C, Forestier N, Dusheiko G, Ferenci P, Pol S, et al. (2009) Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 360: 1839-1850.
10. McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, et al. (2010) Telaprevir for previously treated chronic HCV infection. N Engl J Med 362: 1292-1303.
11. Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, et al. (2010) Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465: 96-100.
12. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, et al. (1995) Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373: 123-126.
13. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD, (1996) HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271: 1582-1586.
14. Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, et al. (1996) Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci U S A 93: 4398-4402.
15. Bonhoeffer S, May RM, Shaw GM, Nowak MA, (1997) Virus dynamics and drug therapy. Proc Natl Acad Sci U S A 94: 6971-6976.
16. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, et al. (1995) Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373: 117-122.
17. Stafford MA, Corey L, Cao Y, Daar ES, Ho DD, et al. (2000) Modeling plasma virus concentration during primary HIV infection. J Theor Biol 203: 285-301.
18. Dixit NM, Markowitz M, Ho DD, Perelson AS, (2004) Estimates of intracellular delay and average drug efficacy from viral load data of HIV-infected individuals under antiretroviral therapy. Antivir Ther 9: 237-246.
19. Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, et al. (1997) Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387: 188-191.
20. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, et al. (1998) Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282: 103-107.
21. Dixit NM, Layden-Almer JE, Layden TJ, Perelson AS, (2004) Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 432: 922-924.
22. Bekkering FC, Neumann AU, Brouwer JT, Levi-Drummer RS, Schalm SW, (2001) Changes in anti-viral effectiveness of interferon after dose reduction in chronic hepatitis C patients: a case control study. BMC Gastroenterol 1: 14.
23. Sentjens RE, Weegink CJ, Beld MG, Cooreman MC, Reesink HW, (2002) Viral kinetics of hepatitis C virus RNA in patients with chronic hepatitis C treated with 18 MU of interferon alpha daily. Eur J Gastroenterol Hepatol 14: 833-840.
24. Herrmann E, Lee JH, Marinos G, Modi M, Zeuzem S, (2003) Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 37: 1351-1358.
25. Dahari H, Ribeiro RM, Perelson AS, (2007) Triphasic decline of hepatitis C virus RNA during antiviral therapy. Hepatology 46: 16-21.
26. Dahari H, Lo A, Ribeiro RM, Perelson AS, (2007) Modeling hepatitis C virus dynamics: liver regeneration and critical drug efficacy. J Theor Biol 247: 371-381.
27. Reluga TC, Dahari H, Perelson AS, (2009) Analysis of Hepatitis C Virus Infection Models with Hepatocyte Homeostasis. SIAM J Appl Math 69: 999-1023.
28. Neumann AU, Lam NP, Dahari H, Davidian M, Wiley TE, et al. (2000) Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis 182: 28-35.
29. Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, et al. (1995) Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 22: 1050-1056.
30. Lopez-Labrador FX, Ampurdanes S, Gimenez-Barcons M, Guilera M, Costa J, et al. (1999) Relationship of the genomic complexity of hepatitis C virus with liver disease severity and response to interferon in patients with chronic HCV genotype 1b infection [correction of interferon]. Hepatology 29: 897-903.
31. Ballardini G, Groff P, Pontisso P, Giostra F, Francesconi R, et al. (1995) Hepatitis C virus (HCV) genotype, tissue HCV antigens, hepatocellular expression of HLA-A,B,C, and intercellular adhesion-1 molecules. Clues to pathogenesis of hepatocellular damage and response to interferon treatment in patients with chronic hepatitis C. J Clin Invest 95: 2067-2075.
32. Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, et al. (2000) Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 132: 517-524.
33. Poynard T, McHutchison J, Davis GL, Esteban-Mur R, Goodman Z, et al. (2000) Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 32: 1131-1137.
34. Shirakawa H, Matsumoto A, Joshita S, Komatsu M, Tanaka N, et al. (2008) Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors. Hepatology 48: 1753-1760.
35. Lam NP, Pitrak D, Speralakis R, Lau AH, Wiley TE, et al. (1997) Effect of obesity on pharmacokinetics and biologic effect of interferon-alpha in hepatitis C. Dig Dis Sci 42: 178-185.
36. Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, et al. (2004) Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 126: 1015-1023; discussion 1947.
37. Alberti A, Chemello L, Noventa F, Cavalletto L, De Salvo G, (1997) Therapy of hepatitis C: re-treatment with alpha interferon. Hepatology 26: 137S-142S.
38. Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, et al. (1997) Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 26: 226-231.
39. Bekkering FC, Stalgis C, McHutchison JG, Brouwer JT, Perelson AS, (2001) Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model. Hepatology 33: 419-423.
40. Chang M, Williams O, Mittler J, Quintanilla A, Carithers RL Jr, et al. (2003) Dynamics of hepatitis C virus replication in human liver. Am J Pathol 163: 433-444.
41. Guedj J, Neumann AU, (2010) Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics. J Theor Biol 267: 330-340.
42. Delang L, Vliegen I, Froeyen M, Neyts J, (2011) Comparative study of the genetic barriers and pathways towards resistance of selective inhibitors of hepatitis C virus replication. Antimicrob Agents Chemother 55: 4103-4113.
43. McCown MF, Rajyaguru S, Le Pogam S, Ali S, Jiang WR, et al. (2008) The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob Agents Chemother 52: 1604-1612.
44. Kamal SM, Fouly AE, Kamel RR, Hockenjos B, Al Tawil A, et al. (2006) Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology 130: 632-638.
45. Matthews GV, Hellard M, Haber P, Yeung B, Marks P, et al. (2009) Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in Acute Hepatitis C. Clin Infect Dis 48: 650-658.
46. Gerlach JT, Diepolder HM, Zachoval R, Gruener NH, Jung MC, et al. (2003) Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 125: 80-88.
47. Licata A, Di Bona D, Schepis F, Shahied L, Craxi A, et al. (2003) When and how to treat acute hepatitis C? J Hepatol 39: 1056-1062.
48. Santantonio T, Fasano M, Sinisi E, Guastadisegni A, Casalino C, et al. (2005) Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. J Hepatol 42: 329-333.